PERSPECTIVE THERAPEUTICS, INC. Shareholders' Equity
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Shareholders' Equity of $323.86 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $323.86M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $347.44M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $207.03M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $242.22M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $323.86M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $347.44M 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $207.03M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $242.22M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $265.69M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $284.64M 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $290.67M 10-Q · filed 2026-08-10 | |
| 2024-09-30 | $328.47M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $341.00M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $229.89M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $75.18M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $98.77M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $108.65M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $118.03M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $54.64M 10-K/A · filed 2025-03-28 | |
| 2022-09-30 | $57.70M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $61.28M 10-K · filed 2024-03-28 | |
| 2022-03-31 | $63.20M 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $64.39M 10-Q · filed 2023-11-14 | |
| 2021-09-30 | $65.76M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $67.41M 10-K · filed 2024-03-28 | |
| 2021-03-31 | $68.10M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $12.77M 10-Q · filed 2022-05-13 | |
| 2020-09-30 | $5.09M 10-Q · filed 2022-05-13 | |
| 2020-06-30 | $5.72M 10-KT · filed 2023-05-01 | |
| 2020-03-31 | $5.82M 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $6.14M 10-Q · filed 2021-05-14 | |
| 2019-09-30 | $6.96M 10-Q · filed 2021-05-14 | |
| 2019-06-30 | $7.68M 10-KT · filed 2023-05-01 | |
| 2019-03-31 | $8.61M 10-Q · filed 2020-05-13 | |
| 2018-12-31 | $9.66M 10-Q · filed 2020-05-13 | |
| 2018-09-30 | $11.11M 10-Q · filed 2020-05-13 | |
| 2018-06-30 | $5.03M 10-K · filed 2021-09-27 | |
| 2018-03-31 | $6.62M 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $7.87M 10-Q · filed 2019-05-10 | |
| 2017-09-30 | $9.15M 10-Q · filed 2019-05-10 | |
| 2017-06-30 | $10.60M 10-K · filed 2020-09-25 | |
| 2017-03-31 | $12.25M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $13.57M 10-Q · filed 2017-02-09 | |
| 2016-09-30 | $14.97M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $16.40M 10-K · filed 2019-09-27 | $16.40M 10-K · filed 2016-09-09 |
| 2016-03-31 | $17.52M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $18.55M 10-Q · filed 2016-02-09 | |
| 2015-09-30 | $19.84M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $20.78M 10-K · filed 2018-09-26 | $20.78M 10-K · filed 2015-09-14 |
| 2015-03-31 | $21.60M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $22.53M 10-Q · filed 2015-02-17 | |
| 2014-09-30 | $23.42M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $23.96M 10-K · filed 2017-09-28 | $23.96M 10-K · filed 2014-09-29 |
| 2014-03-31 | $24.65M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $6.49M 10-Q · filed 2014-02-14 | |
| 2013-09-30 | $7.41M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $5.37M 10-K · filed 2016-09-09 | |
| 2013-03-31 | $6.34M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $7.02M 10-Q · filed 2013-02-14 | |
| 2012-09-30 | $8.16M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $5.82M 10-K · filed 2015-09-14 | |
| 2012-03-31 | $6.15M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $6.68M 10-Q · filed 2012-02-14 | |
| 2011-09-30 | $5.42M 10-Q/A · filed 2011-12-13 | |
| 2011-06-30 | $6.45M 10-K · filed 2013-09-30 | |
| 2010-06-30 | $6.20M 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |